Literature DB >> 18640587

Beta-cell apoptosis in type 2 diabetes: quantitative and functional consequences.

R Lupi1, S Del Prato.   

Abstract

Type 2 diabetes, the most common form of diabetes in humans, is characterized by impaired insulin secretion paralleled by a progressive decline in beta-cell function and chronic insulin resistance. Several authors have showed that in type 2 diabetes there is a reduction of islet and/or insulin-containing cell mass or volume. Regulation of the beta-cell mass appears to involve a balance of beta-cell replication and apoptosis but, at the molecular level, pancreatic beta-cell loss by apoptosis appears to play an important role in the development of insulin deficiency and the onset and/or progression of the disease. The mechanisms favoring apoptosis in type 2 diabetic pancreatic islets and new potential therapeutic approaches to prevent beta-cell death and maintain beta-cell mass are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18640587     DOI: 10.1016/S1262-3636(08)73396-2

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  26 in total

Review 1.  Imaging beta-cell mass and function in situ and in vivo.

Authors:  Lu Yang; Wei Ji; Yanhong Xue; Liangyi Chen
Journal:  J Mol Med (Berl)       Date:  2013-05-23       Impact factor: 4.599

2.  Association of PARL rs3732581 genetic variant with insulin levels, metabolic syndrome and coronary artery disease.

Authors:  Brenda L Powell; Steven Wiltshire; Gillian Arscott; Pamela A McCaskie; Joseph Hung; Brendan M McQuillan; Peter L Thompson; Kim W Carter; Lyle J Palmer; John P Beilby
Journal:  Hum Genet       Date:  2008-08-30       Impact factor: 4.132

3.  Delta cell death in the islet of Langerhans and the progression from normal glucose tolerance to type 2 diabetes in non-human primates (baboon, Papio hamadryas).

Authors:  Rodolfo Guardado Mendoza; Carla Perego; Giovanna Finzi; Stefano La Rosa; Carlo Capella; Lilia M Jimenez-Ceja; Licio A Velloso; Mario J A Saad; Fausto Sessa; Federico Bertuzzi; Stefania Moretti; Edward J Dick; Alberto M Davalli; Franco Folli
Journal:  Diabetologia       Date:  2015-06-07       Impact factor: 10.122

Review 4.  Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?

Authors:  Sachin K Majumdar; Silvio E Inzucchi
Journal:  Endocrine       Date:  2013-01-25       Impact factor: 3.633

5.  Assay development and multivariate scoring for high-content discovery of chemoprotectants of endoplasmic-reticulum-stress-mediated amylin-induced cytotoxicity in pancreatic beta cells.

Authors:  Courtney J Law; Harriet A Ashcroft; Weifan Zheng; Jonathan Z Sexton
Journal:  Assay Drug Dev Technol       Date:  2014-09       Impact factor: 1.738

6.  Pancreatic β cell dedifferentiation in diabetes and redifferentiation following insulin therapy.

Authors:  Zhiyu Wang; Nathaniel W York; Colin G Nichols; Maria S Remedi
Journal:  Cell Metab       Date:  2014-04-17       Impact factor: 27.287

7.  Systematic investigation into the role of intermittent high glucose in pancreatic beta-cells.

Authors:  Chen Shao; Jianqiu Gu; Xin Meng; Hongzhi Zheng; Difei Wang
Journal:  Int J Clin Exp Med       Date:  2015-04-15

8.  Which is the eligible patient to be treated with pioglitazone? The expert view.

Authors:  A Avogaro; M Federici; J Betteridge; R Bonadonna; I W Campbell; G H Schernthaner; B Staels; E Farinaro; G Crepaldi
Journal:  J Endocrinol Invest       Date:  2011-11       Impact factor: 4.256

9.  Effect of gastric bypass combined with ileal transportation on type 2 diabetes mellitus.

Authors:  Zhaoxia Gao; Bin Wang; Xiaojun Gong; Chun Yao; Defa Ren; Liwei Shao; Yan Pang; Jinxiu Liu
Journal:  Exp Ther Med       Date:  2018-03-06       Impact factor: 2.447

10.  Dynamics of beta-cell turnover: evidence for beta-cell turnover and regeneration from sources of beta-cells other than beta-cell replication in the HIP rat.

Authors:  Erica Manesso; Gianna M Toffolo; Yoshifumi Saisho; Alexandra E Butler; Aleksey V Matveyenko; Claudio Cobelli; Peter C Butler
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-05-26       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.